PA-PPG
1.8.2022 15:47:07 CEST | Business Wire | Press release
PPG (NYSE: PPG) today announced PPG INNOVEL® PRO, an enhanced internal spray coating that uses no bisphenol-A (BPA) or bisphenol starting substances and provides more robust application properties for the infinitely recyclable aluminum beverage can.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220801005497/en/
PPG Innovel PRO is a next-generation, high-performance acrylic coating that draws on PPG Innovel ’s nearly 10 years as the market’s most widely used non-BPA internal beverage spray coatings. The company estimates that PPG Innovel coatings have been used on more than 220 billion cans in more than 40 countries to date.
PPG Innovel PRO coating complies with all global food contact standards for consumer safety, and its improved application properties provide operational benefits for can plants around the world.
“The growing and dynamic beverage can industry requires solutions that satisfy all global regulations to remove bisphenols from food contact coatings while ensuring maximum can line production speeds and minimal spoilage,” said Amy Ericson, PPG senior vice president,
Packaging Coatings. “PPG Innovel PRO coating is a future-forward solution that doesn’t rely on BPA or any other bisphenol starting substances while protecting both can and beverage integrity.”
Validated with the PPG SAFEASSURE™ protocol for safe food-contact coating development, PPG Innovel PRO coating reliably supports the ever-widening range of filling goods that beverage brands want to can. It features a lower migration profile than standard epoxy and epoxy-mimic coatings, and all PPG Innovel internal spray coatings have achieved Platinum CRADLE-TO-CRADLE® material health certification from the Cradle-to-Cradle Products Innovation Institute.
“The innovation goes beyond the product itself,” Ericson said. “PPG offers customers a resilient supply chain with manufacturing sites across the globe. The new coating also comes with the support of industry-leading technical and regulatory support teams, which provide on-site expertise to keep customer operations running smoothly. PPG Innovel PRO coating is a big step forward for the industry, enabling major beverage brands to more efficiently offer safer and more sustainable metal-packaged drinks that today’s consumers can feel good about.”
For more information about PPG Innovel coatings, visit www.packagingcoatings.com/en-US/innovel-pro
PPG: WE PROTECT AND BEAUTIFY THE WORLD®
At PPG (NYSE: PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for nearly 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 75 countries and reported net sales of $16.8 billion in 2021. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com .
PPG SafeAssure is a trademark and Innovel, the PPG Logo and We protect and beautify the world are registered trademarks of PPG Industries Ohio, Inc.
Cradle-to-Cradle is a registered trademark of Cradle to Cradle Products Innovation Institute
CATEGORY Packaging Coatings
View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005497/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 14:01:00 CEST | Press release
DCX introduces groundbreaking new safety standard protecting critical AI infrastructure by monitoring and keeping the entire coolant loop Continuous monitoring of eight coolant parameters and automatic dosing keep hall-scale liquid-cooling loops in specification between service visits Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 14:00:00 CEST | Press release
Company’s Third Largest Shareholder Expects Update on Increased Transparency, Strategic Review of Xerox Financial Services Business Unit, and Continued DeleveragingSTARTEEPO Chairman František Bostl to Address Xerox Investment at Skytop Conference in London STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executin
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release
Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release
More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
